REG - C4X Discovery - C4XD and HitGen to collaborate in inflammation

C4X Discovery HoldingsAnnouncement

20/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221020:nRST4791Da&default-theme=true

RNS Number : 4791D  C4X Discovery Holdings PLC  20 October 2022

 

C4XD and HitGen to collaborate in inflammation hit identification project

 

Initial project with option to expand collaboration on successful outputs

 

20 October 2022 - C4X Discovery Holdings plc ("C4XD", AIM: C4XD), a pioneering
Drug Discovery company, and Shanghai Stock Exchange listed company HitGen Inc.
("HitGen", SSE: 688222.SH), a world leader in the development and application
of DNA-encoded library (DEL) technology, today announce a research
collaboration project to identify novel, small molecule hits against an
inflammatory target for further C4XD development.

 

The aim of the project is to augment C4XD's growing pipeline of small molecule
inflammatory disease candidates for pre-clinical development and out-licensing
to the pharmaceutical industry.  In this initial collaboration, C4XD and
HitGen have together developed an approach for HitGen to apply its DEL
screening technology platform to identify hits against a commercially valuable
target for inflammatory diseases.  If successful, C4XD will then apply its
molecule design Conformetrix technology to translate these hits into suitable
starting points for a small molecule programme, which can then be progressed
through C4XD's rigorous Drug Discovery process.  C4XD has the option to
extend the collaboration with HitGen during this Drug Discovery phase to
leverage HitGen's growing R&D capabilities.

 

Dr. Clive Dix, CEO of C4XD, said: "In line with our strategy to collaborate
with innovative technology partners, C4XD extensively evaluates the small
molecule discovery landscape and builds relationships with high potential
complementary companies.  We believe this collaboration with HitGen gives us
access to a world-leading screening technology, which perfectly complements
both our Drug Discovery expertise and Conformetrix technology and could enable
C4XD to unlock a highly challenging target in inflammation.  We are looking
forward to working with their team and continuing to build on this exciting
relationship."

 

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen, said:
"C4XD is a highly innovative company and has developed some very high-value
assets using their proprietary Conformetrix technology. Combining their
expertise with HitGen's world leading DNA-encoded library technology platform,
we look forward to identifying good starting points for further development
into valuable leads for the inflammatory target. We hope the collaboration
could eventually turn into a strong partnership to deliver a number of
solutions for highly unmet medical needs."

 

- Ends -

 

 

Contacts

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977
 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)
 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders.  Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development.  Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.  For further
information, see our website: www.C4XDiscovery.com
(http://www.C4XDiscovery.com)

 

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with
headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston,
USA. HitGen has established leading technology platforms to enable the
discovery and optimization of small molecules and nucleic acid drugs.  Our
key technology platforms include DNA-encoded library technology (DEL),
fragment-based drug discovery and structure-based drug design technologies
(FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and
targeted protein degradation technology (TPD).  Through our diverse and
flexible business models, we have built up collaboration partnership with
several hundred biopharmaceutical research organizations worldwide.  HitGen
has multiple programmes from early discovery to clinical trial stage.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit
www.hitgen.com (http://www.hitgen.com) .

For media inquiries: media@hitgen.com (mailto:media@hitgen.com)

For investor inquiries: investors@hitgen.com (mailto:investors@hitgen.com)

For business development: bd@hitgen.com (mailto:bd@hitgen.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPENFDFAFFA